Efficacy of Dapsone 5% gel in treatment of Acne vulgaris
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20163502Keywords:
Acne vulgaris, Dapsone 5% gelAbstract
Background: Acne vulgaris is chronic inflammatory disorder of pilosebaceous unit mainly characterized by comedones, papules and nodulocystic lesions affecting face and upper trunk. Topical dapsone 5% gel is approved to treat acne vulgaris because of its anti-inflammatory and anti-bacterial activities.
Methods: A single center, open label interventional study was conducted during 1 year period in dermatology OPD of Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra. Patients were enrolled in the study considering inclusion criteria. Patients were asked to apply dapsone 5% gel twice daily on face for 12 week. Efficacy was evaluated by mean percent reduction in total, inflammatory and non-inflammatory lesions and success rate on change in investigator global acne severity assessment scale while tolerability was assessed by evaluating skin dryness, erythema, stinging or burning sensation and scaling at baseline, 1, 2, 4, 8 and 12 week.
Results: At end of 12 week, success rate reached to 31.54%. Dapsone 5% gel was effective in reduction of total, non-inflammatory and inflammatory lesions by 57.75%, 52% and 63.1% respectively. Side effects with dapsone gel were tolerable, mild and transient.
Conclusions: Dapsone 5% gel was efficacious and well tolerated in non-inflammatory as well as inflammatory acne lesions.
Metrics
References
Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-80.
Demircay Z, Seckin D, Senol A, Demir F. Patient's perspective: an important issue not to be overlooked in assessing acne severity. Eur J Dermatol. 2008;18(2):181-4.
Zaidi Z. Acne vulgaris-an update on patho-physiology and treatment. J Pak Med Assoc. 2009;59:635-7.
Stein Gold LF. What’s new in acne and inflammation. J Drugs Dermatol. 2013;12(6):67-9.
Weiss JS. Messages from molecules: deciphering the code. J Drugs Dermatol. 2013;12(6):70-2.
Bellew S, Thiboutot D, Del Rosso JQ. Pathogenesis of acne vulgaris: what’s new, what’s interesting and what may be clinically relevant. J Drugs Dermatol. 2011;10(6):582-5.
Jeremy AHT, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion Initiation. J Invest Dermatol. 2003;121:20-7.
Zouboulis C. Propionibacterium acnes and Sebaceous Lipogenesis: A Love-Hate Relationship? J Invest Dermatol. 2009;129:2093-6.
Ottaviani M, Alestas T, Flori E, Mastorfrancesco A, Zouboulis CC, Picardo M. Peroxidated squalene induces the production of inflammatory mediators in HaCaT keratinocytes: a possible role in acne vulgaris? J Invest Dermatol. 2006;126:2430-7.
Jeremy AHT, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion Initiation. J Invest Dermatol. 2003;121:20-7.
Kircik L. Harnessing the anti-inflammatory effects of topical dapsone for management of acne. J Drugs Dermatol. 2010;9(6):667-71.
Kaminsky A. Less Common Methods to Treat Acne. Dermatology. 2003;206:68-73.
Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961;73:367-70.
Stotland M, Shalita AR, Kissling RF. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. Am J Clin Dermatol. 2009;10:221-7.
Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatmentof acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.
Beutler E. G6PD deficiency. Blood. 1994;84(11):3613-6.
Thiboutot DM, Willmer J, Sharata HH, Alder R, Garrett S. Pharmacokinetics of dapsone gel 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007;46(8)697-712.
Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5% for the treatment of acne vulgaris; safety and efficacy of long term (1 year) treatment. J Drugs Dermatol. 2007;6(10):981-7.
Pickert A, Raimer S. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10:1515-21.
Del Rosso JQ. Newer topical therapies for the treatment of acne vulgaris. Cutis. 2007;80(5):400-10.
Raimer S, Maloney JM, Bourcier M, Wilson D, Papp K, Siegfried E, et al. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis. 2008;81:171-8.
